CD262 Antibody, anti-mouse, PE, REAfinity™ 130-124-480 from Miltenyi Biotec

Product Specs
ItemCD262 Antibody, anti-mouse, PE, REAfinity™
CompanyMiltenyi Biotec
Price $70.00Supplier Page View Company Product Page
Catalog Number130-124-480
Research AreaFor research use only
Regulatory StatusFor research use only
TypeAntibodies
Source/Expression Systemhuman cell line
ReactivityMouse (Ms)
Clonalitymonoclonal
NCBI Gene AliasesDR5, KILLER, Ly98, MK, TRAILR2, TRICK2A, TRICK2B, TRICKB
NCBI Full Gene Nametumor necrosis factor receptor superfamily, member 10b
ApplicationsFlow Cytometry (FCM)
Hosthuman cell line
CloneREA1233
IsotypeREA Control Antibody, human IgG1
TargetCD262
FormatReagents are supplied in buffer containing stabilizer and 0.05% sodium azide
Conjugate/TagPE
Concentration1:50
Quantity30 µg in 200 µL

Local Office

Miltenyi Biotec Inc.

2303 Lindbergh Street

Auburn, CA 95602

United States

Phone: Phone: +1 530 888 8871
Toll Free: 800 FOR MACS
Fax: +1 530 888 8925

Email: macs@miltenyibiotec.com

International Office

Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68

51429 Bergisch Gladbach

Germany

Phone: +49 2204 8306-0
Fax: +49 2204 8306-235

Email: macs@miltenyibiotec.de

(1) Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapyCancer researchMay 1, 2010Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, et al.

(2) Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cellsJournal of virologyJune 1, 2009Iannello A, Samarani S, Debbeche O, Ahmad R, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A.

(3) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibodyJournal of the National Cancer InstituteMay 7, 2008Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.

(4) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapseJournal of immunology (Baltimore, Md. : 1950)April 1, 2005Sato K, Nakaoka T, Yamashita N, Yagita H, Kawasaki H, Morimoto C, Baba M, Matsuyama T.

(5) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapyThe Journal of experimental medicineFebruary 16, 2004Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, et al.

(6) NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacyJournal of immunology (Baltimore, Md. : 1950)January 1, 2004Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, Chambers BJ.

CD262 Antibody, anti-mouse, PE, REAfinity™ from Miltenyi Biotec